Which anti‑helminthic agents are safe for a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?

Safe Antihelminthic Agents for G6PD-Deficient Patients

Most common antihelminthic medications (albendazole, mebendazole, pyrantel pamoate, praziquantel, ivermectin) are safe for patients with G6PD deficiency, as there is no evidence linking these agents to hemolysis in G6PD-deficient individuals.

Key Evidence-Based Recommendations

The provided evidence focuses primarily on antimalarial agents rather than antihelminthics, but the principles are directly applicable:

Medications to AVOID in G6PD Deficiency

Based on solid evidence, only seven medications have proven hemolytic risk 1:

• Dapsone
• Methylthioninium chloride (methylene blue)
• Nitrofurantoin
• Phenazopyridine
• Primaquine (antimalarial, not antihelminthic)
• Rasburicase
• Tolonium chloride (toluidine blue)

None of these are standard antihelminthic agents.

Safe Antihelminthic Options

Standard antihelminthic medications are NOT on the prohibited list and can be used safely:

• Albendazole - No evidence contraindicates use
• Mebendazole - No evidence contraindicates use
• Pyrantel pamoate - No evidence contraindicates use
• Praziquantel - No evidence contraindicates use
• Ivermectin - No evidence contraindicates use

Important Clinical Context

The Overestimation Problem

A 2024 real-world study of 31,962 G6PD-deficient patients found that only 0.2% experienced major hemolysis requiring hospitalization, with 71.8% caused by fava beans, 8.5% by infections, and only 4.2% potentially medication-related 2. This demonstrates that many medications historically labeled as "risky" have been wrongly cited, often because they were administered during infection-related hemolytic episodes 1.

G6PD Variant Considerations

While relevant for antimalarials (particularly primaquine), this is less critical for standard antihelminthics:

• African variant (A-) has mild deficiency with relative resistance to drug-induced hemolysis 3
• Mediterranean variant (B-) has higher hemolysis risk 3

For standard antihelminthics, variant type does not alter safety profile since these agents lack oxidant properties.

Clinical Pitfalls to Avoid

1. Do not confuse antimalarials with antihelminthics: Primaquine is an antimalarial that causes hemolysis in G6PD deficiency, but it is NOT used for helminthic infections

2. Do not withhold necessary antihelminthic treatment: There is no evidence-based reason to avoid standard antihelminthic agents in G6PD-deficient patients 1

3. Infection itself can trigger hemolysis: If hemolysis occurs during treatment, consider the underlying infection as the culprit rather than automatically blaming the medication 2, 1

Practical Algorithm

For any G6PD-deficient patient requiring antihelminthic treatment:

1. Prescribe standard antihelminthic agents (albendazole, mebendazole, pyrantel pamoate, praziquantel, ivermectin) without restriction
2. Avoid the seven proven hemolytic agents listed above (none are antihelminthics)
3. Monitor for hemolysis if concurrent infection is severe
4. Do not perform routine G6PD testing before prescribing standard antihelminthics—it is unnecessary